SCHEMBL4070926

SCHEMBL4070926

Cc1cc2c(c(Oc3ccccc3)n1)C(=O)OCC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.43
CYP2C19 P33261 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
KDM4E B2RXH2 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
CYP2C9 P11712 2/20 0.37
MAPT P10636 2/20 0.37
MAPK1 P28482 2/20 0.37
ATM Q13315 1/20 0.37
HTT P42858 4/20 0.36
LMNA P02545 1/20 0.35
GAA P10253 2/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
TSHR P16473 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4070664 0.82 KDM4E (0.41) SMN1; SMN2L3MBTL1ALDH1A1HPGDHSD17B10
SCHEMBL4786364 0.77 PGR (0.47) CYP1A2CYP2C19SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL4065342 0.77 L3MBTL1 (0.45) L3MBTL1ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL4243371 0.75 GAA (0.37) SMN1; SMN2L3MBTL1ALDH1A1HPGDHSD17B10
SCHEMBL4063497 0.75 KDM4E (0.44) L3MBTL1ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL4070413 0.74 ALDH1A1 (0.43) CYP1A2SMN1; SMN2L3MBTL1ALDH1A1HPGD
SCHEMBL4065469 0.73 ALDH1A1 (0.43) SMN1; SMN2L3MBTL1ALDH1A1HPGDHSD17B10
SCHEMBL4066514 0.73 GAA (0.43) SMN1; SMN2L3MBTL1ALDH1A1HPGDHSD17B10
SCHEMBL4070347 0.73 GAA (0.43) L3MBTL1ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL4747170 0.73 ADORA2A (0.45) ALDH1A1HPGDHSD17B10KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US claimed
WO-2008123756-A1 A PHARMACEUTICAL COMPOSITIONS CONTAINING LACTON TYPE PYRIDINE DERIVATIVES AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION AND TREATMENT OF ISCHEMIA SK CHEMICALS CO., LTD. (KR) 2008-10-16 WO claimed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US claimed
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US disclosed
EP-1706412-A4 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS CO LTD (KR) 2009-03-18 EP disclosed
WO-2008123756-A1 A PHARMACEUTICAL COMPOSITIONS CONTAINING LACTON TYPE PYRIDINE DERIVATIVES AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION AND TREATMENT OF ISCHEMIA SK CHEMICALS CO., LTD. (KR) 2008-10-16 WO disclosed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US disclosed
EP-1706412-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK Chemicals, Co., Ltd. (KR) 2006-10-04 EP disclosed
WO-2005063768-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS, CO., LTD. (KR) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same IL5, IL1B, P2RY4 CYP1A2 161/4885CYP2C19 155/4885SMN1; SMN2 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.